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Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex
ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to
collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies.The delivery of unproven stem cell-based interventions
(SCBIs) is widespread, and sometimes involves businesses
engaging in direct-to-consumer (DTC) marketing to
patients. The industry using DTC marketing comprises
individual clinics worldwide as well as highly organized
business alliances operating within advanced economies,
such as Australia, Japan, and the United States. Approxi-
mately a decade ago, this industry consisted mainly of
clinics offering a diverse range of purported stem cell ther-
apies derived from multiple sources (e.g., adipose tissue,
bone marrow, embryonic tissue, fetal tissue, placental tis-
sue, and umbilical cord blood) (Lau et al., 2008). Themajor-
ity of firms, especially those in developed economies, now
administer unproven uses of autologous biomaterials, pri-
marily harvested from fat or bonemarrow,with some deliv-
ering SCBIs in the context of ‘‘pay-to-participate’’ clinical
research. Both of these approaches may minimize legal lia-
bility (Turner and Knoepfler, 2016; Turner, 2017). The use
of ‘‘adult’’ stem cells has also been characterized as a means
of avoiding ethical concerns particular to embryonic stem
cells (Bianco et al., 2013). However, their premature use
in the clinical setting raises other challenging issues.
While the desire to access potentially therapeutic inter-
ventions is completely understandable, many patients
stand to be harmed by receiving unproven SCBIs as evi-
denced by recent cases of tumor formation and blindness
following stem cell injections (Berkowitz et al., 2016; Kur-
iyan et al., 2017). Such occurrences also threaten to incur
substantial health care costs due to adverse events and
derail the legitimate field of regenerative medicine. Of
note, the delivery of unproven SCBIs has occurred in the
context of widespread medical consumerism, dominant
neoliberal ideologies of health care, and the privileging of
patient autonomy (including the ‘‘right to try’’ movement)
over the integrity and social importance of translationalresearch in the development of therapeutic evidence.
The introduction of ‘‘coverage with evidence’’ schemes
(whereby payment is made for experimental approaches
as data about safety and efficacy are obtained) around the
globe and streamlined market authorization pathways for
stem cell-based products in major health markets such as
Japan and the United States may also limit the ability to
assess the safety and effectiveness of emerging and existing
therapies (Sipp, 2015; Lee and Lysaght, 2018).
Patients seeking information about SCBIs commonly
navigate masses of conflicting information and contend-
ing claims found in DTC advertising, news articles, media,
and blogs and from various ‘‘accidental advisors,’’ who are
asked for advice about available treatments (Petersen et al.,
2015). For those seeking an option to ‘‘do something,’’
attempting to establish the credibility of different infor-
mation sources is a tortuous undertaking (Tanner et al.,
2017). The increasing sophistication of online advertising
has compounded the difficulties faced, with many busi-
nesses incorporating ‘‘tokens of scientific legitimacy’’ into
their marketing strategies (Munsie et al., 2017; Sipp et al.,
2017). Such strategies may reinforce patients’ beliefs in
the trustworthiness and reputability of clinic operators.
The ethical issues raised by the delivery of SCBIs include
those related to: respecting the autonomous wishes of pa-
tients and their families to access potentially beneficial
interventions; maximizing the likelihood that current
and future patients benefit and are not unnecessarily
harmed in the process of receiving SCBIs; ensuring that
claims about SCBIs are accurate and understandable; and
working toward the fair allocation of resources in the devel-
opment and delivery of such interventions. Regulators, sci-
entists, clinicians, and professional societies are positioned
to articulate ethical expectations and to set clear standards
regarding the appropriate uses of SCBIs. Following theStem Cell Reports j Vol. 11 j 1021–1025 j November 13, 2018 j 1021
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(International Society of StemCell Research)Meeting (Mel-
bourne, Australia, June 2018), each of these possibilities is
described in turn, followed by some novel approaches
that promise to help alleviate some of the current problems
related to SCBIs.
Regulators: Developing Coordinated Frameworks
In most major healthcare markets, stem cell research and
treatments are regulated under complex frameworks that
involve multiple agencies and institutional actors.
Changes in the regulation of the potentially valuable mar-
ket for new regenerative medicine products have also been
introduced as a means of increasing national economic
competitiveness. As a result, there is insufficient alignment
and coordination between regulators with authority over
the various domains of research, clinical practice, and prod-
uct manufacturing and marketing in relation to stem cell
research and treatment. Internationally, there are differ-
ences in the legal mechanisms, technical language, and
entities that regulate the various domains. However, there
are also similarities in how these frameworks generally
separate regulatory responsibilities according to sharp dis-
tinctions that are typically drawn between research and
clinical practice.
The separation of regulatory responsibilities reflect ‘‘silos’’
thatmayhavenot only enabled the growthof theDTCmar-
ket for stemcells, butmayalso behampering the translation
of stem cell research into demonstrably safe and efficacious
products.Many countries thathave invested in thebasic sci-
ence and translationof stemcell researchhave adopted a so-
called ‘‘risk-based approach.’’ This approach generally sets
out an evidence-based pathway for the manufacture and
marketing of stem cells as medicinal or advanced therapy
productswhile allowingpatients to accessmedical interven-
tions with stem cells in the context of clinical care (Lysaght
et al., 2017). Medical interventions do not fall under the
jurisdiction of product regulatory authorities, but are
instead regulated under separate, and often de-centralized,
governance frameworks for professional practice.
Allowing products that lack the evidence necessary for
market licensure to be provided in the context of clinical
care may discourage investment in product development.
If manufacturers can generate revenue without needing
to demonstrate this level of evidence, there is little incen-
tive for them to invest in expensive, late-phase clinical
trials capable of formally determining safety and efficacy.
Moreover, exemptions that permit the production of
stem cells for clinical use without the market entry barriers
of regulatory approval provide an unfair competitive
advantage against manufacturers willing to invest in effi-
cacy trials. Both situations introduce inefficiencies and un-
certainties into the clinical translation process that place1022 Stem Cell Reports j Vol. 11 j 1021–1025 j November 13, 2018patients at risk, burden public health systems with poten-
tially ineffective products, delay access to information
about the optimal usage of products that may provide
benefit (Kimmelman and London, 2015), and run the risk
of derailing cellular approaches to regenerative medicine.
A lack of enforcement of laws in place to protect consumers
from unprofessional marketing practices has also contrib-
uted to products being available without sound evidence
of safety and efficacy.
With no single authority responsible across these
domains, more coherent and coordinated frameworks are
needed to better align the ethics and regulation of
biomedical innovation. For this purpose, a cooperative
regulatorymodel that spansmultiple domainsof regulation
is needed (Lysaght et al., 2018). Such a model could poten-
tially bridge the current silos that regulate innovation
pathways in clinical researchandpractice through the estab-
lishment, implementation, and enforcement of evidence-
based standards for cell processing and manufacturing, for
marketingSCBIs, andfor introducingtheminto routineclin-
ical care. This cooperativemodel is consistentwith calls for a
coordinated approach to reduce the risks associated with
DTC marketing of unproven stem cell products and incen-
tivize scientifically grounded, clinically meaningful, and
socially valuable innovation (Sipp et al., 2017).
In addition, attention should be directed at developing
regulatory standards with respect to the use of social media
platforms designed to target DTC marketing of SCBIs to
people based on their online activity. This is especially
important for those who may be newly diagnosed or
injured and thereby uniquely vulnerable to aggressive sales
techniques that promise cures at a reduced (yet still
substantial) cost within a very short time period lest the
opportunity be lost. In addition, some of these therapies
are targeting patients with certain neurological disorders
that bring with them issues of whether patients truly un-
derstand what is being said given that these conditions
can cause major cognitive problems.
Scientists: Harmonizing Standards and
Comprehensive Reporting of Experiences
Clear professional standards for developing and testing
SCBIs have been articulated (see http://www.isscr.org/docs/
default-source/all-isscr-guidelines/guidelines-2016/isscr-
guidelines-for-stem-cell-research-and-clinical-translation.pdf?
sfvrsn=4). Importantly, assessing the ethical acceptability
of particular research initiatives requires incorporating scien-
tific expertise. This is necessary in order to evaluate not only
the scientific rationale emerging from in vitro, and when
applicable, in vivo results, but also the risk of abnormal cell
function, immunological reactions, the modification of the
pathological micro-environment, and long-term health ef-
fects. Unfortunately, many SCBIs are now discussed with
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careful assessment of the rationale as to why that therapy
should or would work in the condition being treated.
This having been said, uniform standards for cell
processing, manufacture, and control should be harmo-
nized by international groups of scientists, cell banks,
and regulators since stem cells react in response to different
stimuli, requiring uniformity and definition of references
to assure a realistic prediction of risks and benefits in clin-
ical translation. Mechanisms need to be developed to
encourage and/or require the publication of medium- and
long-term clinical outcomes, which will facilitate better
categorization of the risks of SCBIs. Similarly, reports are
needed not only in the cases of success, but also when there
are negative results and adverse events.
Clinicians: Managing Competing Obligations
Doctors are increasingly exhorted to practice patient-
centered or person-centered medicine, to respect patients’
autonomy, to support their judgements, and to share
decision-making with them. At the same time doctors are
expected to practice evidence-based medicine, to use
limited health resources wisely, to avoid over-diagnosis
and over-treatment, and to adhere to precepts of medical
professionalism. The central challenge for clinicians is
that none of these ideas are ethically or epistemologically
unproblematic and all create different obligations in
healthcare settings. This challenge is becoming more com-
mon as healthcare ‘‘knowledge’’ becomes more democra-
tized, biomedical technology becomes more complex,
and the traditional standards of therapeutic evidence
collapse. Requests by patients for unproven SCBIs illustrate
the tensions physicians face in seeking to protect both their
patients and the public interest.
Physicians have obvious professional obligations to
recommend SCBIs of proven safety and efficacy to their
patients. In addition, they should compassionately help
patients understand the potential hazards of using un-
proven SCBIs and apprise them of reasonable alternative
therapeutic approaches. Furthermore, physicians ought
not to deliver unproven SCBIs except under very limited
settings that constitute responsible innovation or in the
context of approved research protocols (see http://www.
isscr.org/docs/default-source/all-isscr-guidelines/guidelines-
2016/isscr-guidelines-for-stem-cell-research-and-clinical-
translation.pdf?sfvrsn=4 and http://www.isscr.org/docs/
default-source/clinical-resources/isscr-stem-cell-based-
clnical-trials-practical-advice_final_23jan2018.pdf).
Professional Societies: Enhancing and Implementing
Standards for Clinical Translation
Professional societies, such as the ISSCR, have a vested
interest in ensuring the integrity of stem cell researchand the ethically appropriate use of SCBIs. Toward such
ends, the ISSCR has issued and updated guidelines (see
http://www.isscr.org/docs/default-source/all-isscr-guidelines/
guidelines-2016/isscr-guidelines-for-stem-cell-research-and-
clinical-translation.pdf?sfvrsn=4) in this regard and
has provided an array of resources for patients consid-
ering SCBIs (http://www.closerlookatstemcells.org/patient-
resources/). The International Society for Cellular Thera-
pies has issued similar statements and resources (see
https://www.celltherapysociety.org/page/UCT). Some medi-
cal societies have also issued expected standards in the clin-
ical provision of SCBIs for their respective members (see
https://www.aao.org/clinical-statement/intraocular-stem-
cell-therapy; www.thoracic.org/members/assemblies/
assemblies/rcmb/working-groups/stem-cell/resources/
statement-on-unproven-stem-cell-interventions-for-lung-
diseases.pdf; https://www.acsep.org.au/content/Document/
ACSEP%20Stem%20Cell%20Position%20Statement%20
Nov17%20Final(1).pdf).
Despite such efforts, there are at least two key nodes in
the clinical translation pipeline that should be better regu-
lated andmademore accountable: ethics review boards and
the physicians acting as principal investigators in clinical
trials. Both need to be able to assess not only what a clinical
trial is attempting to show, but also the basis for the therapy
and the rigor with which it is being tested. The focus of
such evaluations should not be limited to safety concerns
but should address the rationale for the proposed trial
and the robustness of the preclinical science underpinning
its claims. Both ethics review boards and physicians also
have a responsibility to facilitate clinical translation while
also protecting patients during these efforts. The process
by which they should assess these therapies needs to be
better articulated and better supported (Barker et al.
2018). How exactly one does the latter is variable, but a
number of possibilities exist, such as setting up interna-
tional teams of experts who can offer impartial advice on
any such trials. Professional societies can and should help
develop approaches to doing so.
Discussion
Addressing the ethical issues inherent to the delivery of un-
proven SCBIs will clearly need to involve the coordinated
efforts of: regulators to fill gaps in current policies and to
enforce them; scientists engaging in responsible research;
clinicians delivering SCBIs that are likely to be helpful;
and professional societies articulating appropriate stan-
dards and guidelines. In addition, there are some other ap-
proaches that should be considered, such aswell-structured
and independently funded registries, engaging in social
media discussions, and finding ways for informed patients
to have meaningful conversations with other patients
about particular SCBIs. Working in partnership withStem Cell Reports j Vol. 11 j 1021–1025 j November 13, 2018 1023
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tion statements of professional societies are translated into
accessible language and resources for particular patient
groups may also assist people in distinguishing legitimate
research and treatments from exploitative commercial
practice (see https://www.acsep.org.au/content/Document/
ACSEP%20Stem%20Cell%20Position%20Statement%20
Nov17%20Final(1).pdf).
Outcome registries have been enormously helpful in
enhancing understanding of hematopoietic stem cell
transplants (Horowitz 2008). In addition, registries are
often proposed as a way of helping to assess the long-
term benefits and harms associated with innovative thera-
pies or those that are approvedwith little long-term clinical
outcome data. Accordingly, consideration should be given
to creating a registry for SCBIs. To be most useful, such a
registry would need to capture high-quality clinical data
and be well curated. However, it is unclear who might be
able to undertake such curation and support this work.
Public funding for a well-maintained, stringent outcomes
registry could provide a beneficial resource. However,
mechanisms need to be developed to protect against using
any such registry as a token of legitimacy by those who are
inappropriately delivering SCBIs, as has happened on occa-
sions with the clinicaltrials.gov website.
Social media is increasingly playing an influential role in
sustaining the market for SCBIs. Consequently, scientists,
clinicians, and professional societies should consider the
possibility of engaging in social media conversations
regarding stem cell research and SCBIs so that accurate in-
formation can be introduced in an accessible fashion and
to potentially counter spurious claims about the high
benefits and low risks of many SCBIs that are amplified
via social media. Nevertheless, doing so is fraught with
challenges related to time and resources, developing
effective communication skills, the potential for misattri-
butions or uses of postings and aggressive backlash and
trolling by those keen to protect their own interests.
Finally, although there are a range of web-based resources
(including those mentioned above) for patients who are
contemplating SCBIs as a possible option to alleviate their
suffering, such resources alone may not be powerful
enough to overcome the seductive messages of hope
offered byDTCmarketing. One novel approach to consider
would be to find ways for patients to ‘‘talk’’ to other
patients regarding what is known about particular diseases
and conditions and treatments for them. If patient advo-
cacy groups could become even more meaningfully
engaged with scientists and clinicians conducting respon-
sible research regarding SCBIs, they would be better posi-
tioned to talk with other patients about the current state
of evidence regarding particular SCBIs and when and
why caution should be exercised in seeking treatment1024 Stem Cell Reports j Vol. 11 j 1021–1025 j November 13, 2018with them. However, care must be taken in identifying or-
ganizations that do not have financial or other ties to the
industry engaged in the premature delivery of unproven
SCBIs. At the same time, it is important to recognize the
very real possibility that patient and consumer advocacy
groups may, simply by virtue of their illness experiences,
increase utilization of unproven but widely hyped clinical
interventions.
While it is unclear what processes would best work to
support and address the ethical issues in the delivery of
SCBIs, there are several promising approaches that should
be considered, some of which we have articulated here.DECLARATION OF INTERESTS
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